Reached Enrollment Goal of 305 Patients Living With Type 1 or Type 2 Diabetes Primary Endpoint Analysis Expected in 4q 2024 Data Dissemination and Fda Submission Expected in 2025
MannKind Corporation (United States), 2024. Reached Enrollment Goal of 305 Patients Living With Type 1 or Type 2 Diabetes Primary Endpoint Analysis Expected in 4q 2024 Data Dissemination and Fda Submission Expected in 2025, MannKind Corporation (United States).
United States of America.
Retrieved from https://coilink.org/20.500.12592/3ji8v3y on 15 Nov 2024. COI: 20.500.12592/3ji8v3y.